Zydus Lifesciences added 1.38% to Rs 891.60 after it received final approval from US Food & Drug Administration (USFDA) for manufacturing and marketing of Isosorbide Mononitrate extended-release tablets.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.